Research programme: anti-infectives - Cidara Therapeutics

Drug Profile

Research programme: anti-infectives - Cidara Therapeutics

Alternative Names: C 001; C 016; CD 201

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Seachaid Pharmaceuticals
  • Developer Cidara Therapeutics
  • Class Antibacterials; Antifungals; Antivirals; Echinocandins; Immunotherapies; Small molecules
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Aspergillosis; Gram-negative infections; Viral infections

Most Recent Events

  • 22 Apr 2017 Antimicrobial data from a preclinical study in Gram-negative infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 28 Feb 2017 Cidara Therapeutics has patents pending for CD 201 and the CloudbreakTM immunotherapy platform
  • 21 Sep 2016 Cidara Therapeutics intends to file an IND application with the US FDA in USA for Gram-negative bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top